Police raid striking doctors' homes, offices, after deadline passes on return-to-work order
Yoon touts improved Japan ties on Independence Movement Day as gateway to 'new world'
Tensions loom as doctors plan mass rally in deepening clash over med school quota
DP leader Lee retains ticket to his constituency for April elections
Korean stocks benefit from Zuckerberg's Seoul visit
[EYE] A Buddhist temple where animal spirits find peace
[Weekender] Car camping: How solo female campers enjoy outdoors
S. Korea's meat consumption exceeds rice intakes for 2nd year
South Korea publicly orders some doctors who walked off the job back to work
Korea faces long road in unlocking corporate value like Japan
Celltrion’s anticancer biosimilar Vegzelma authorized for sales in JapanBy Kan Hyeong-woo
Published : Sept. 27, 2022 - 16:34
Celltrion’s Vegzelma, a bevacizumab anticancer biosimilar referencing Avastin, has been approved for sales in Japan, the South Korean biopharmaceutical company said Tuesday.
According to Celltrion, the Japanese Ministry of Health, Labor and Welfare on Monday granted Vegzelma marketing approval for the treatment of multiple types of cancer including colorectal cancer, non-small cell lung cancer, ovarian cancer and cervical cancer.
The latest sales authorization of Vegzelma came after the company obtained two consecutive green lights from the European Commission in August and the UK’s Medicines and Healthcare products Regulatory Agency earlier this month.
IQVIA, a global drug product market tracker, estimated the worldwide market size of bevacizumab to have reached $6.4 billion (9 trillion won) in 2021 with Japan accounting for $782 million as the second biggest market behind the US.
“Following Herzuma that is continuously growing in the Japanese market, we will swiftly release Vegzelma to the market and do our best to strengthen Celltrion’s anticancer antibody biosimilar portfolio,” said a Celltrion official.
Herzuma, Celltrion’s another anticancer biosimilar used to treat breast cancer and stomach cancer, took up 54 percent of the market share in Japan as of the first quarter this year, according to the Celltrion group’s marketing and distribution firm Celltrion Healthcare.
Tensions loom as doctors plan mass rally
Seoul's 1st spy satellite sends images of Pyongyang
Ex-PPP leader to run for seat in less conservative Hwaseong city